Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report released on Friday morning,Benzinga reports. The firm currently has a $200.00 price objective on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently weighed in on the company. Royal Bank of Canada increased their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 23rd. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Finally, Robert W. Baird increased their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ:JAZZ opened at $126.67 on Friday. The stock’s fifty day simple moving average is $113.29 and its 200-day simple moving average is $110.62. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a market capitalization of $7.66 billion, a P/E ratio of 17.84, a P/E/G ratio of 0.98 and a beta of 0.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Activity

In other news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This trade represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Coldstream Capital Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after buying an additional 165 shares during the last quarter. MidWestOne Financial Group Inc. boosted its stake in Jazz Pharmaceuticals by 5.4% during the 3rd quarter. MidWestOne Financial Group Inc. now owns 22,063 shares of the specialty pharmaceutical company’s stock valued at $2,458,000 after acquiring an additional 1,134 shares during the last quarter. Barclays PLC grew its holdings in Jazz Pharmaceuticals by 19.1% during the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock worth $4,369,000 after acquiring an additional 6,289 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in Jazz Pharmaceuticals during the 3rd quarter worth $2,491,000. Finally, XTX Topco Ltd increased its position in shares of Jazz Pharmaceuticals by 57.5% in the 3rd quarter. XTX Topco Ltd now owns 11,631 shares of the specialty pharmaceutical company’s stock worth $1,296,000 after purchasing an additional 4,245 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.